Establishment of newly cancer therapy for expression of target molecules with cancer stem cells in ovarian carcinoma

我们认为，通过分析卵巢癌干细胞表达的分子，选择对卵巢癌干细胞更特异的分子，并将其用作治疗的标志物，建立一种新的选择性癌症治疗方法，可以获得良好的治疗结果。首先，在细胞周期的GO期，我们检测到三个基因：与抗癌药物外排相关的ABCG 2，GO期抑制基因FOXO 3a和特异性表达的泛素连接酶亚基F bw7。我们还检测到调节ABCG 2基因的microRNA在GO细胞中的高表达。而采用SP法检测透明细胞腺癌中的癌干细胞，其中包括高频率的SP细胞。由于这些细胞表现出与临床图像相似的脂肪细胞样特征，并且脂肪细胞特异性基因PPARγ高度表达，因此抗癌药物不能很好地发挥作用并维持细胞的未分化。我们在malcroarray检测到了类似的基因。

We assumed that we can obtain favorable therapy results by establishing a new selective cancer therapy through analyzing an expressed molecular to ovarian cancer stem cells, selecting more specific molecular to ovarian cancer stem cells, and use them as a marker for the therapy. Firstly, In cell cycle GO phase, we detected three genes ; ABCG2 which relate to anticancer drug efflux, FOXO3a that is a GO phase suppressor gene and specific expression of ubiquitin ligases subunites F bw7. We also detected high expression of microRNA for regulating ABCG2 gene in GO cells. Whereas, By side population (SP) method, we detected the cancer stem cell in clear cell ademocarcinoma which include high frequency SP cells. Since these cells showed adipocytes-like character similar to a clinical picture and PPARγ that specific gene to adipocytes was highly expressed, an anticancer drug does not effect well and maintain of cell undifferentiation. We detected similar genes at malcroarray.